The Board of Directors of the Company at its meeting held today November 5 2025 has inter alia considered and approved the standalone and consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30 2025 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. We enclose herewith the said Unaudited Financial Results of the Company along with the Limited Review Reports issued by the Statutory Auditors.
Aurobindo Pharma: Board Meeting Outcome for Outcome Of The Board Meeting Held On November 5 2025
November 5, 2025
Download PDF
Aurobindo Pharma
Informed fund ideas, better judgment. Every month. Mutual Fund Insight, every month since October 2002.
Take charge. Know more. Keep more. Mutual Fund Insight helps you do all three — every month